Brokerages Set LENZ Therapeutics, Inc. (NASDAQ:LENZ) Price Target at $45.60

Shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ) have been assigned a consensus rating of “Moderate Buy” from the eight ratings firms that are presently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and six have given a buy recommendation to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $44.00.

A number of research analysts recently weighed in on LENZ shares. Bank of America reduced their price objective on shares of LENZ Therapeutics from $35.00 to $29.00 and set a “buy” rating for the company in a research note on Wednesday, March 25th. Wall Street Zen lowered shares of LENZ Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. Weiss Ratings lowered shares of LENZ Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday. HC Wainwright reduced their price target on shares of LENZ Therapeutics from $56.00 to $48.00 and set a “buy” rating for the company in a research report on Tuesday. Finally, William Blair restated an “outperform” rating on shares of LENZ Therapeutics in a research report on Tuesday, March 10th.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in LENZ. Creative Planning purchased a new position in shares of LENZ Therapeutics during the 2nd quarter valued at $412,000. JPMorgan Chase & Co. grew its position in shares of LENZ Therapeutics by 28.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 10,361 shares of the company’s stock valued at $304,000 after purchasing an additional 2,310 shares in the last quarter. Legal & General Group Plc lifted its holdings in shares of LENZ Therapeutics by 25.7% during the 2nd quarter. Legal & General Group Plc now owns 10,989 shares of the company’s stock worth $322,000 after acquiring an additional 2,247 shares during the last quarter. Rhumbline Advisers lifted its holdings in shares of LENZ Therapeutics by 35.6% during the 2nd quarter. Rhumbline Advisers now owns 24,363 shares of the company’s stock worth $714,000 after acquiring an additional 6,396 shares during the last quarter. Finally, Russell Investments Group Ltd. lifted its holdings in shares of LENZ Therapeutics by 1,105,675.0% during the 2nd quarter. Russell Investments Group Ltd. now owns 44,231 shares of the company’s stock worth $1,296,000 after acquiring an additional 44,227 shares during the last quarter. 54.32% of the stock is currently owned by hedge funds and other institutional investors.

More LENZ Therapeutics News

Here are the key news stories impacting LENZ Therapeutics this week:

• Positive Sentiment: HC Wainwright continues to carry a “Buy” rating and a $48.00 price target on LENZ, signaling analyst conviction that there remains significant upside relative to the current share price despite the estimate reductions. HC Wainwright Lowers LENZ Therapeutics (NASDAQ:LENZ) Price Target to $48.00
• Neutral Sentiment: LENZ was included in a broader healthcare analyst roundup (coverage mention only); this keeps the company on analysts’ radar but did not provide new company‑specific catalysts. Analysts Offer Insights on Healthcare Companies
• Negative Sentiment: HC Wainwright materially lowered Q1–Q4 2026 EPS forecasts (Q1 now ($1.11), Q2 ($1.06), Q3 ($0.90), Q4 ($0.83)) and cut FY2026 to ($3.89). These nearer‑term downgrades indicate weaker revenue/earnings visibility for 2026 and are a primary driver of downward pressure on the stock.
• Negative Sentiment: Longer‑term estimates were also trimmed: FY2027 moved to ($2.72), FY2028 to ($0.88), FY2029 to $0.61 and FY2030 to $2.38 (all revised lower), which delays expected profitability and reduces long‑term upside assumptions embedded in prior models.

LENZ Therapeutics Trading Down 8.4%

LENZ Therapeutics stock opened at $9.15 on Tuesday. LENZ Therapeutics has a 1-year low of $8.25 and a 1-year high of $50.40. The firm has a market capitalization of $286.85 million, a price-to-earnings ratio of -3.26 and a beta of 0.66. The firm has a 50 day simple moving average of $10.99 and a 200 day simple moving average of $19.69.

LENZ Therapeutics (NASDAQ:LENZ) last released its quarterly earnings data on Tuesday, March 24th. The company reported ($1.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.91) by ($0.25). The company had revenue of $1.59 million for the quarter, compared to analyst estimates of $3.09 million. On average, equities research analysts forecast that LENZ Therapeutics will post -3.88 EPS for the current year.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.